Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149146 | 0.89 | POLB (0.38) | KDM4DPTGESPOLBKMT2AALDH1A1 | |
| SCHEMBL5618639 | 0.88 | POLB (0.37) | PTGESPOLBALDH1A1 | |
| SCHEMBL17849000 | 0.78 | MEN1 (0.37) | KMT2A | |
| SCHEMBL2721332 | 0.76 | PRMT3 (0.37) | KMT2A | |
| SCHEMBL19210479 | 0.75 | CYP2D6 (0.32) | KMT2A | |
| Hydrochloric Acid SCHEMBL837377 | 0.75 | KDM4A (0.36) | KMT2A | |
| SCHEMBL1584053 | 0.75 | POLB (0.32) | POLBKMT2A | |
| SCHEMBL2520169 | 0.74 | — | — | |
| SCHEMBL387476 | 0.74 | SIGMAR1 (0.57) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26105931 | 0.73 | ALOX15 (0.36) | KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | KDM4D 3798/4885PTGES 3931/4885POLB 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.